<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03610438</url>
  </required_header>
  <id_info>
    <org_study_id>ALL2418</org_study_id>
    <secondary_id>2018-003006-32</secondary_id>
    <nct_id>NCT03610438</nct_id>
  </id_info>
  <brief_title>Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia</brief_title>
  <acronym>ALL2418</acronym>
  <official_title>A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients With B-Cell Acute Lymphoblastic Leukemia With Positive Minimal Residual Disease Before Any Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, phase 2A exploratory study of feasibility and effectiveness of
      Inotuzumab Ozagomicin in adult patients with Acute Lymphoid Leukemia (ALL) with positive
      minimal residual disease before any hematopoietic stem cell transplantation.

      The study is divided in two cohorts; cohort 1 will enroll 38 Ph+ patients, cohort 2 will
      enroll 38 Ph- patients, as defined with statistical analysis. The two cohorts will have the
      same treatment, with the exception of short term and long term maintenance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2019</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is divided in two cohorts; cohort 1 will enroll 38 Ph+ patients, cohort 2 will enroll 38 Ph- patients, as defined with statistical analysis. The two cohorts will have the same treatment, with the exception of short term and long term maintenance.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients obtaining a negative Minimal Residual Disease (MRD)</measure>
    <time_frame>Two years after study entry.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients alive</measure>
    <time_frame>Two years from start of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events in MRD positive patients</measure>
    <time_frame>Two years after study entry.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Acute Lymphoid Leukemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 will entroll 38 Ph+ patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 will enroll 38 Ph- patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inotuzumab Ozogamicin (IO)</intervention_name>
    <description>After course 1 MRD will be evaluated:
- patients MRD negative will enter into short maintenance or long maintenance according to investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inotuzumab Ozogamicin (IO)</intervention_name>
    <description>After course 2 MRD will be evaluated; patients MRD negative will enter into short maintenance or long maintenance by investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ph+ ALL with p190 or p210 detectable and measurable (at least 10-4 x10000 ABL) after
             at least 3 months of any therapy, or the failure of at least 2 TKI.

          -  Ph- ALL with detectable and measurable IG specific transcript after at least 2 courses
             of previous therapy.

          -  Age ≥ 18 years old.

          -  ECOG ≤ 2.

        Exclusion Criteria:

          -  More than 5% of BM blasts.

          -  WHO performance status ≤ 50% (Karnofsky) or ≥ 3 (ECOG).

          -  Active HBV or HCV hepatitis, or AST/ALT ≥ 2.5 x ULN and bilirubine ≥ 1.5 x ULN.

          -  Evidence of liver fibrosis, portal hypertension or other clinically relevant liver
             abnormalities at screening liver ultrasonography.

          -  History of alcohol abuse.

          -  Burkitt lymphoma and active CNS leukemia. Patients with previuos neurological
             toxicitiy as well co-morbidity will be carefully evaluated for enrolment.

          -  Ongoing or active infections.

          -  Uncontrolled hypertriglyceridemia (triglycerides &gt;450 mg/dL). Clinically significant,
             uncontrolled, or active cardiovascular disease.

          -  Uncontrolled hypertension (diastolic blood pressure &gt;90 mm Hg; systolic &gt;140 mm Hg).
             Patients with hypertension should be under treatment on study entry to effect blood
             pressure control.

          -  Creatinine level &gt; 2.5mg/dl or Glomerular Filtration Rate (GFR) &lt; 20 ml/min or
             proteinuria &gt; 3.5 g/day.

          -  Documented inherited protrombotic disorders

          -  Patients who have received any investigational drug ≤ 4 weeks.

          -  Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or
             who have not recovered from side effects of such therapy.

          -  Patients with a history of another primary malignancy that is currently clinically
             significant or currently requires active intervention or with a life expectancy due to
             other malignancy &lt;6 months.

          -  Patients that have received Inotuzumab or Anti CD22 directed therapies before

          -  Patients with known hereditary coagulopathy

          -  Patient that received during their life diagnosis of VOD or had ongoing VOD

          -  Patients who are pregnant or breastfeeding and adults of reproductive potential not
             employing an effective method of birth control (women of childbearing potential must
             have a negative serum pregnancy test within 48 hrs prior to administration of
             induction therapy). Postmenopausal women must be amenorrheic for at least 12 months to
             be considered of non-childbearing potential. Male and female patients must agree to
             employ an effective barrier method of birth control throughout the study and for up to
             4 months following discontinuation of study drugs.

          -  Patients unwilling or unable to comply with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Martinelli</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabio Ciceri</last_name>
    <role>Study Director</role>
    <affiliation>Istituto S. Raffaele, Milan, Italy Giuseppe Saglio, Institute of Hematology, Ospedale Mauriziano, Turin, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <phone>+39 06 70390514</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <phone>+39 06 70390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aou Ospedali Riuniti &quot;Umberto I - G.M. Lancisi - G. Salesi&quot;- Ancona- Sod Clinica Ematologica</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivieri</last_name>
    </contact>
    <investigator>
      <last_name>Attilio Olivieri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>As Dell'Alto Adige, Ospedale Centrale Di Bolzano - Ematologia E Centro Trapianto Midollo Osseo</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mosna</last_name>
    </contact>
    <investigator>
      <last_name>Federico Mosna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irccs Aou San Martino - Genova - Uo Clinica Ematologica</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lemoli</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Massimo Lemoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asl Lecce, Ospedale 'V. Fazzi' - Uo Ematologia</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Di Renzo</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.R.S.T. Srl Irccs - Meldola - Sc Oncologia Medica</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cangini</last_name>
    </contact>
    <investigator>
      <last_name>Delia Cangini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo Di Oncologia Irccs - Milano - Divisione Di Oncoematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todisco</last_name>
    </contact>
    <investigator>
      <last_name>Elisabetta Todisco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ao Ospedali Riuniti Villa Sofia Cervello - Palermo - Uo Ematologia Con Utmo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mulè</last_name>
    </contact>
    <investigator>
      <last_name>Antonino Mulè</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Ircss Policlinico San Matteo - Pavia - Uo Ematologia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zappasodi</last_name>
    </contact>
    <investigator>
      <last_name>Patrizia Zappasodi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asl Pescara, Presidio Ospedaliero 'Spirito Santo' - Uoc Ematologia Clinica</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spadano</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Spadano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ausl Della Romagna, Ospedale &quot;Infermi&quot; - Rimini - Uo Ematologia</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mianulli</last_name>
    </contact>
    <investigator>
      <last_name>Anna Maria Mianulli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asl Roma 2, Ospedale S. Eugenio- Ospedale S.Eugenio - Uoc Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>De Fabritiis</last_name>
    </contact>
    <investigator>
      <last_name>Paolo De Fabritiis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Degli Studi Di Roma &quot;Sapienza&quot; - Dipartimento Di Medicina Traslazionale E Di Precisione - U.O.C. Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiaretti</last_name>
    </contact>
    <investigator>
      <last_name>Sabina Chiaretti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aou &quot;San Giovanni Di Dio E Ruggi D'Aragona&quot; - Salerno - Uoc Ematologia E Trapianti Di Cellule Staminali Emopoietiche</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selleri</last_name>
    </contact>
    <investigator>
      <last_name>Carmine Selleri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aou Senese - Uoc Ematologia E Trapianti</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bocchia</last_name>
    </contact>
    <investigator>
      <last_name>Monica Bocchia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aou Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette - Torino - Sc Ematologia 2</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audisio</last_name>
    </contact>
    <investigator>
      <last_name>Ernesta Audisio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Di Ematologia - Presidio Ospedaliero Di Treviso - Azienda Ulss N.2 Marca Trevigiana</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Endri</last_name>
    </contact>
    <investigator>
      <last_name>Mauro Endri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asui Di Udine - Presidio Ospedaliero &quot;Santa Maria Della Misericordia&quot; - Clinica Ematologica</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candoni</last_name>
    </contact>
    <investigator>
      <last_name>Anna Candoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aou Integrata Di Verona, Policlinico G.B. Rossi - Uoc Ematologia</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonifacio</last_name>
    </contact>
    <investigator>
      <last_name>Massimiliano Bonifacio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoid Leukemia</keyword>
  <keyword>Inotuzumab Ozogamicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inotuzumab Ozogamicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

